Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine.

Simone de Vries LentschBritt W H van der ArendIrene de BoerErik W van ZwetAntoinette MaassenVanDenBrinkGisela M Terwindt

Published in: European journal of neurology (2023)

Anti-CGRP (ligand or receptor) monoclonals lead to improvement of depressive symptoms in individuals with migraine, independent of migraine reduction. Depression may predict treatment response to erenumab but not to fremanezumab.

Keyphrases

depressive symptoms
sleep quality
social support
genome wide
gene expression
dna methylation
combination therapy
transcription factor
replacement therapy
smoking cessation